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Background
Dialyzable leukocyte extracts (DLE) are human blood
derived peptides less than 12kDa in size. DLE are
hypothesized to induce a TH1 response, which makes
them useful in the treatment of allergic disease. The
purpose of this study was to determine the changes in
symptomatology of patients with moderate and severe
allergic rhinitis treated with standard treatment plus
DLE.
Methods
We analyzed the clinical files of 68 patients receiving
dialyzable leukocyte extracts as adjuvant treatment for
moderate to severe allergic rhinitis in the period
between 2009 and 2013, at our immunology department.
All patients receiving DLE signed an informed consent
as part of a running protocol (IC-12-001) authorized by
the ethics committee and health department. Patients
had different standard treatments for allergic rhinitis,
such as antihistamines, nasal corticosteroids, leukotriene
inhibitors and immunotherapy in varying combinations.
Oral DLE was added to standard treatment in patients
that remained symptomatic. The initial DLE dose varied
between 1 and 2 Units (5mL/Unit) per week.
Results
28 (53.8%) female and 24 (46.2%) male patients ages
0-64 with a mean age of 17.3±17.5yrs with moderate to
severe allergic rhinitis added DLE to their treatment.
After 1 to 5 months, 52 (76.5%) reported improved
symptoms, 11 (16.2%) abandoned treatment, 5 (7.4%)
reported no improvement. No patients presented severe
adverse effects. Of the 52 patients who reported
improvement, 6 (11.5%) were asymptomatic, 32 (61.5%)
mentioned general improvement of symptoms, 4 (7.7%)
reported only decreased nasal congestion, 13 (25%)
reported less frequent upper respiratory infections.
2 patients (3.8%) with concomitant asthma suspended
the use of bronchodilators.
Conclusions
DLE may be beneficial as adjuvant treatment for allergic
rhinitis. Although patient self-reported improvement is
subjective, this study lays the ground for more objective
measurements of drug response in the future. Interest-
ingly, it helped decrease the use of bronchodilators in 2
cases with concomitant asthma.
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